trending Market Intelligence /marketintelligence/en/news-insights/trending/U1SWKcx6sSUcEb2GjmnuEw2 content esgSubNav
In This List

Midatech Pharma, Novartis sign licensing deal for cancer compound

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Midatech Pharma, Novartis sign licensing deal for cancer compound

Midatech Pharma PLC secured the rights to a cancer compound from Novartis AG.

Financial terms of the deal were not disclosed.

Under the global license agreement, Midatech Pharma will develop panobinostat, a pan-HDAC inhibitor meant to treat certain brain tumors. The compound was shown to outperform more than 80 anti-cancer agents in a study, the specialty pharmaceutical company said in a news release.

Clinical studies in patients are planned to commence during 2017.